3 Houston innovators to know this week

who's who

This week's roundup of Houston innovators includes Jason Pesterfield of Optellum, Jane Stricker of HETI, and Michael Lee of Octopus Energy. Photos courtesy

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from health tech to clean energy — recently making headlines in Houston innovation.

Jason Pesterfield, CEO of Optellum

Jason Pesterfield joins the Houston Innovators Podcast to share how he plans on getting the company to commercialization right here from Houston. Photo courtesy of Optellum

Last year, Optellum, based in the United Kingdom, opened its United States headquarters in Houston, and shortly after Jason Pesterfield joined to lead the team. On a recent Houston Innovators Podcast episode, Pesterfield explained it's just the start of the company's presence in Houston.

"We're really at the beginning of it," he says. "This is the epicenter of medicine within the United States. There's no bigger or better place for health care than Houston. It's great to be a part of that and to have access to those facilities and those world class physicians and care teams." Read more.

Jane Stricker, executive director of the Houston Energy Transition Initiative at the GHP

These organizations are teaming up to advance development of a regional clean industrial hub. Photo courtesy of GHP

The Houston Energy Transition Initiative and the Center for Houston’s Future have teamed up with the Mission Possible Partnership to lead the city of Houston through the accelerated development of a regional clean industrial hub geared at decarbonization of the industrial sector, including petrochemicals, cement plants, heavy transportation, and more.

The two-year project is focused on development and deployment of clean energy projects — such as "low-carbon hydrogen, carbon capture, use and storage, electrification of industrial processes, and the production and use of low carbon fuels," according to a press release.

“There is no geography in the world better positioned to support the transition to and integration of abundant, low-carbon energy solutions than Houston," says Jane Stricker, executive director and senior vice president of HETI, in the release. "As the Energy Transition Capital of the World, Houston is leveraging its energy leadership to accelerate global solutions for a low-carbon future. This partnership with MPP is a critical component in the region’s efforts to develop and deploy technologies, policies and strategies for broad decarbonization." Read more.

Michael Lee, CEO of Octopus Energy US

Now is the time for your tech company to become a climate company, says this Houston expert. Photo via LinkedIn

In a guest column for InnovationMap, Michael Lee, CEO of Octopus Energy, called for tech innovators to change lanes to focus on the climatetech industry.

"We used to say, 'every company will become a tech company.' We’re now moving towards a world where 'every company is a climate company,'" Lee writes. "And that is creating opportunities throughout the economy for people to contribute their skills and support their families while building something that actually matters." Read more.

Jason Pesterfield, CEO of Optellum, joins the Houston Innovators Podcast to share how he plans on getting the company to commercialization right here from Houston. Photo courtesy of Optellum

Houston innovator gears up for commercialization for AI-driven lung cancer diagnostic tool

HOUSTON INNOVATORS PODCAST EPISODE 164

When a United Kingdom-based, artificial intelligence-driven lung cancer detection tool opened its United States headquarters in Houston, the company tasked Jason Pesterfield with the role of CEO to oversee international expansion and commercialization strategy. Pesterfield, who's based out of the Texas Medical Center's Innovation Institute, is familiar with the job he's been hired to do — that's because he's done it before.

After spending almost two decades at medical technology company, Stryker, Pesterfield joined St. Louis-based Veran Medical Technologies, a company also focused on lung cancer detection, and grew the business over 8 years years to a $30 million-plus annual revenue company before it was acquired by Olympus Corp. in 2020.

After assisting with the transition, he was approached by U.K.-based Optellum's Founder Timor Kadir about taking the reins of Optellum last year to again help scale the early stage digital health company.

"I'm not a computer scientist or an algorithm guy, but I do have experience in commercialization, leading teams, building culture, acquire great talent, working with my team to build a great strategy, and working with investors to make sure we're in a good financial position," Pesterfield says on the Houston Innovators Podcast.

Optellum was founded in 2016, and first entered the Houston market by way of the TMC's accelerator program and its BioBridge with the U.K. The company's technology is an AI platform that helps practitioners diagnose and treat early-stage lung cancer. The software uses natural language processing to scan medical reports of nodules in the lungs to give health care providers more information on cancer diagnostics — an analysis that takes just seconds.

"It's like having a hundred thousand sets of eyes looking over a physician's shoulder," Pesterfield says.

In September, the company raised a $14 million series A round of funding, and Pesterfield explains how that funding is being deployed to focus on growing teams within sales, B2B support, and its research and development pipeline.

He explains on the show that Optellum is just getting started with its relationship within the Houston innovation ecosystem. Pesterfield says Optellum is even on the path to securing its first Houston-based customer.

Pesterfield share more on Optellum's future on the podcast. Listen to the interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.

Optellum, Liongard, and Cart.com have hired new members to their executive teams. Photos courtesy

Updated: 3 Houston startups make strategic C-suite hires

short stories

A handful of Houston tech startups have recently announced new appointments to their C-suites. A med tech company with its national headquarters in Houston has a new leader, a Houston software has a new exec focused on strategy, and a e-commerce company has a new chief revenue officer.

Optellum names new CEO

Jason Pesterfield will lead United States operations for Optellum. Photo courtesy of Optellum

Optellum, a medical software startup based in the United Kingdom and has its United States HQ in Houston, has appointed Jason Pesterfield as CEO to lead growth in the U.S. clinical market. Optellum AI-based software enhances early lung cancer diagnosis and therapy with its medical device software platform, Virtual Nodule Clinic.

Pesterfield was previously the president and CEO of Veran Medical Technologies, a leader in image-guided lung cancer diagnosis. He brings 25 years of leadership experience in the medtech sector. Optellum was founded by Václav Potěšil, Lyndsey Pickup, Timor Kadir, Professor Sir Mike Brady, and Jérôme Declerck.

"It took us almost a year to find the right successor who shares our vision and has the right expertise to take Optellum on to the next stage of growth," says Potěšil in a news release. "I am really excited to work with Jason, to make Optellum's platform available to every clinician in the USA and around the world, and to help them diagnose their lung cancer patients as early as possible. With Jason on board, I can focus on advancing Optellum's vision to transform early lung cancer therapy through partnerships that harness the power of AI software combined with molecular diagnostics, robotics and interventional devices, and drugs."

Liongard announces chief strategy officer

Patrick Schneidau is the chief strategy officer for Liongard. Photo courtesy

Houston software-as-a-service company, Liongard, has named Patrick Schneidau as chief strategy officer. The company, founded in 2015, was a 2021 InnovationMap Awards finalist and reported that the team was looking to expand by around 70 new hires over the next year.

"Liongard is an incredible Houston growth story," Schneidau tells InnovationMap. "Our founders, Joe Alapat and Vincent Tran, have built a first-class team that allow technology service providers to operate at 10x by providing unprecedented insight and data into the systems deployed in the modern IT stack. In a rapidly growing market, they are quickly becoming 'must have' technology. I'm excited to join to team to accelerate their growth into new markets and with new products."

Schneidau spent over a decade at Houston-based PROS before serving in C-level positions at two other Houston startups — Commtrex and Truss. He's also previously served as talent committee chair for Houston Exponential.

Cart.com hires a new chief revenue officer

Randy Ray is Cart.com's first chief revenue officer. Photo courtesy of Cart.com

Fresh off its $98 million series B, Cart.com has named its first chief revenue officer. Randy Ray is tasked with driving sales growth across the company. He has over 15 years of sales and operations experience and was previously senior vice president at supply-chain solution provider High Jump.

"I've worked with the world's biggest retail and SaaS brands, and I've seen the need for a unified Ecommerce-as-a-Service hub to create operational efficiencies and unlock scalable success," Ray says in a press release. "I'm a firm believer in the Cart.com mission to drive success for online brands, and I'm looking forward to tripling our sales organization and building out a world-class revenue infrastructure as we take the company global over the next 6 to 9 months."

Ad Placement 300x100

Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Texas tops ranking of best state for investors in new report

by the numbers

Texas ranks third on a new list of the best states for investors and startups.

Investment platform BrokerChooser weighed five factors to come up with its ranking:

2024 Google search volume for terms related to investing
Number of investors
Number of businesses receiving investments in 2024
Total amount of capital invested in businesses in 2024
Percentage change in amount of investment from 2019 to 2024

Based on those figures, provided mostly by Crunchbase, Texas sits at No. 3 on the list, behind No. 1 California and No. 2 New York.

Especially noteworthy for Texas is its investment total for 2024: more than $164.5 billion. From 2019 to 2024, the state saw a 440 percent jump in business investments, according to BrokerChooser. The same percentages are 204 percent for California and 396 percent for New York.

“There is definitely development and diversification in the American investment landscape, with impressive growth in areas that used to fly under the radar,” says Adam Nasli, head analyst at BrokerChooser.

According to Crunchbase, funding for Texas startups is off to a strong start in 2025. In the first three months of this year, venture capital investors poured nearly $2.9 billion into Lone Star State companies, Crunchbase data shows. Crunchbase attributes that healthy dollar amount to “enthusiasm around cybersecurity, defense tech, robotics, and de-extincting mammoths.”

During the first quarter of this year, roughly two-thirds of VC funding in Texas went to just five companies, says Crunchbase. Those companies are Austin-based Apptronik, Austin-based Colossal Biosciences, Dallas-based Island, Austin-based NinjaOne, and Austin-based Saronic.

Autonomous truck company rolls out driverless Houston-Dallas route

up and running

Houston is helping drive the evolution of self-driving freight trucks.

In October, Aurora opened a more than 90,000-square-foot terminal at a Fallbrook Drive logistics hub in northwest Houston to support the launch of its first “lane” for driverless trucks—a Houston-to-Dallas route on the Interstate 45 corridor. Aurora opened its Dallas-area terminal in April and the company began regular driverless customer deliveries between the two Texas cities on April 27.

Close to half of all truck freight in Texas moves along I-45 between Houston and Dallas.

“Now, we are the first company to successfully and safely operate a commercial driverless trucking service on public roads. Riding in the back seat for our inaugural trip was an honor of a lifetime – the Aurora Driver performed perfectly and it’s a moment I’ll never forget,” Chris Urmson, CEO and co-founder of Pittsburgh-based Aurora, said in a news release.

Aurora produces software that controls autonomous vehicles and is known for its flagship product, the Aurora Driver. The software is installed in Volvo and Paccar trucks, the latter of which includes brands like Kenworth and Peterbilt.

Aurora previously hauled more than 75 loads per week under the supervision of vehicle operators from Houston to Dallas and Fort Worth to El Paso for customers in its pilot project, including FedEx, Uber Freight and Werner. To date, it has completed over 1,200 miles without a driver.

The company launched its new Houston to Dallas route with customers Uber Freight and Hirschbach Motor Lines, which ran supervised commercial pilots with Aurora.

“Transforming an old school industry like trucking is never easy, but we can’t ignore the safety and efficiency benefits this technology can deliver. Autonomous trucks aren’t just going to help grow our business – they’re also going to give our drivers better lives by handling the lengthier and less desirable routes,” Richard Stocking, CEO of Hirschbach Motor Lines, added in the statement.

The company plans to expand its service to El Paso and Phoenix by the end of 2025.

“These new, autonomous semis on the I-45 corridor will efficiently move products, create jobs, and help make our roadways safer,” Gov. Greg Abbott added in the release. “Texas offers businesses the freedom to succeed, and the Aurora Driver will further spur economic growth and job creation in Texas. Together through innovation, we will build a stronger, more prosperous Texas for generations.”

In July, Aurora said it raised $820 million in capital to fuel its growth—growth that’s being accompanied by scrutiny.

In light of recent controversies surrounding self-driving vehicles, the International Brotherhood of Teamsters, whose union members include over-the-road truckers, recently sent a letter to Lt. Gov. Dan Patrick calling for a ban on autonomous vehicles in Texas.

“The Teamsters believe that a human operator is needed in every vehicle—and that goes beyond partisan politics,” the letter states. “State legislators have a solemn duty in this matter to keep dangerous autonomous vehicles off our streets and keep Texans safe. Autonomous vehicles are not ready for prime time, and we urge you to act before someone in our community gets killed.”

Houston cell therapy company launches second-phase clinical trial

fighting cancer

A Houston cell therapy company has dosed its first patient in a Phase 2 clinical trial. March Biosciences is testing the efficacy of MB-105, a CD5-targeted CAR-T cell therapy for patients with relapsed or refractory CD5-positive T-cell lymphoma.

Last year, InnovationMap reported that March Biosciences had closed its series A with a $28.4 million raise. Now, the company, co-founded by Sarah Hein, Max Mamonkin and Malcolm Brenner, is ready to enroll a total of 46 patients in its study of people with difficult-to-treat cancer.

The trial will be conducted at cancer centers around the United States, but the first dose took place locally, at The University of Texas MD Anderson Cancer Center. Dr. Swaminathan P. Iyer, a professor in the department of lymphoma/myeloma at MD Anderson, is leading the trial.

“This represents a significant milestone in advancing MB-105 as a potential treatment option for patients with T-cell lymphoma who currently face extremely limited therapeutic choices,” Hein, who serves as CEO, says. “CAR-T therapies have revolutionized the treatment of B-cell lymphomas and leukemias but have not successfully addressed the rarer T-cell lymphomas and leukemias. We are optimistic that this larger trial will further validate MB-105's potential to address the critical unmet needs of these patients and look forward to reporting our first clinical readouts.”

The Phase 1 trial showed promise for MB-105 in terms of both safety and efficacy. That means that potentially concerning side effects, including neurological events and cytokine release above grade 3, were not observed. Those results were published last year, noting lasting remissions.

In January 2025, MB-105 won an orphan drug designation from the FDA. That results in seven years of market exclusivity if the drug is approved, as well as development incentives along the way.

The trial is enrolling its single-arm, two-stage study on ClinicalTrials.gov. For patients with stubborn blood cancers, the drug is providing new hope.

View All Listings

INNOVATIONMAP EMAILS ARE AWESOME